{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T23:49:27Z","timestamp":1761176967916,"version":"build-2065373602"},"reference-count":52,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"am","delay-in-days":361,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion Clinique et Biologique"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.tracli.2021.08.347","type":"journal-article","created":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T20:12:13Z","timestamp":1630181533000},"page":"380-385","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Traitement du purpura thrombotique thrombocytop\u00e9nique auto-immun\u00a0: un tournant d\u00e9cisif"],"prefix":"10.1016","volume":"28","author":[{"given":"P.","family":"Poullin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tracli.2021.08.347_bib0265","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/jth.13571","article-title":"Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies","volume":"15","author":"Scully","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.tracli.2021.08.347_bib0270","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","article-title":"Thrombotic thrombocytopenic purpura","volume":"129","author":"Joly","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2021.08.347_bib0275","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1182\/blood.2020008021","article-title":"A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP","volume":"137","author":"Coppo","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2021.08.347_bib0280","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1111\/jth.15006","article-title":"ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.tracli.2021.08.347_bib0285","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/S2352-3026(17)30026-1","article-title":"Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: A cohort study","volume":"4","author":"Bendapudi","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.tracli.2021.08.347_bib0290","doi-asserted-by":"crossref","first-page":"e10208","DOI":"10.1371\/journal.pone.0010208","article-title":"Predictive features of severe acquired ADAMTS13\u00a0deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience","volume":"5","author":"Coppo","year":"2010","journal-title":"PloS One"},{"key":"10.1016\/j.tracli.2021.08.347_bib0295","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/rth2.12461","article-title":"Diagnosis and follow-up of thrombotic thrombocytopenic purpura with an automated chemiluminescent ADAMTS13\u00a0activity immunoassay","volume":"5","author":"Beranger","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.tracli.2021.08.347_bib0300","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/jth.15010","article-title":"ISTH guidelines for treatment of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.tracli.2021.08.347_bib0305","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/vox.12090","article-title":"Characterization of the complications associated with plasma exchange for thrombotic thrombocytopaenic purpura and related thrombotic microangiopathic anaemias: a single institution experience","volume":"106","author":"McGuckin","year":"2014","journal-title":"Vox Sang"},{"key":"10.1016\/j.tracli.2021.08.347_bib0310","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/trf.15721","article-title":"Deaths and complications associated with the management of acute immune thrombotic thrombocytopenic purpura","volume":"60","author":"Colling","year":"2020","journal-title":"Transfusion (Paris)"},{"key":"10.1016\/j.tracli.2021.08.347_bib0315","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1111\/trf.13229","article-title":"Type of plasma preparation used for plasma exchange and clinical outcome of adult patients with acquired idiopathic thrombotic thrombocytopenic purpura: a French retrospective multicenter cohort study","volume":"55","author":"Toussaint-Hacquard","year":"2015","journal-title":"Transfusion (Paris)"},{"key":"10.1016\/j.tracli.2021.08.347_bib0320","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.tracli.2017.10.002","article-title":"Amotosalen-inactivated plasma is as equally well tolerated as quarantine plasma in patients undergoing large volume therapeutic plasma exchange","volume":"25","author":"Guignier","year":"2018","journal-title":"Transfus Clin Biol"},{"key":"10.1016\/j.tracli.2021.08.347_bib0325","doi-asserted-by":"crossref","first-page":"102587","DOI":"10.1016\/j.transci.2019.07.002","article-title":"Efficacy and safety of plasma exchange using a double viral inactivated and prion reduced solvent\/detergent fresh frozen plasma for the treatment of thrombotic microangiopathy: The first French experience in a single center","volume":"59","author":"Poullin","year":"2020","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.tracli.2021.08.347_bib0330","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1182\/bloodadvances.2017009308","article-title":"Cyclosporine or steroids as an adjunct to plasma exchange in the treatment of immune-mediated thrombotic thrombocytopenic purpura","volume":"1","author":"Cataland","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.tracli.2021.08.347_bib0335","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00277-009-0877-5","article-title":"High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized study","volume":"89","author":"Balduini","year":"2010","journal-title":"Ann Hematol"},{"key":"10.1016\/j.tracli.2021.08.347_bib0340","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/nep.13234","article-title":"Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand","volume":"28","author":"Fox","year":"2018","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.tracli.2021.08.347_bib0345","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12185-017-2264-7","article-title":"Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) 2017\u00a0in Japan","volume":"106","author":"Matsumoto","year":"2017","journal-title":"Int J Hematol"},{"key":"10.1016\/j.tracli.2021.08.347_bib0350","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.ejim.2015.07.021","article-title":"Rituximab in autoimmune thrombotic thrombocytopenic purpura: A success story","volume":"26","author":"Froissart","year":"2015","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.tracli.2021.08.347_bib0355","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1182\/blood-2011-03-341131","article-title":"A phase 2\u00a0study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura","volume":"118","author":"Scully","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2021.08.347_bib0360","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/ajh.24559","article-title":"Efficacy of a rituximab regimen based on B cell depletion in thrombotic thrombocytopenic purpura with suboptimal response to standard treatment: Results of a phase II, multicenter noncomparative study","volume":"91","author":"Benhamou","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.tracli.2021.08.347_bib0365","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/jth.12114","article-title":"Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse","volume":"11","author":"Westwood","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.tracli.2021.08.347_bib0370","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1007\/s00134-016-4662-3","article-title":"Understanding therapeutic targets in thrombotic thrombocytopenic purpura","volume":"43","author":"Joly","year":"2017","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.tracli.2021.08.347_bib0375","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1111\/trf.13586","article-title":"Prognostic risk-stratified score for predicting mortality in hospitalized patients with thrombotic thrombocytopenic purpura: nationally representative data from 2007\u00a0to 2012","volume":"56","author":"Goel","year":"2016","journal-title":"Transfusion (Paris)"},{"key":"10.1016\/j.tracli.2021.08.347_bib0380","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/jth.12790","article-title":"Cardiac troponin-I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. Experience of the French Thrombotic Microangiopathies Reference Center","volume":"13","author":"Benhamou","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.tracli.2021.08.347_bib0385","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tracli.2021.08.347_bib0390","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tracli.2021.08.347_bib0395","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1182\/blood.2020007599","article-title":"Real-world experience with caplacizumab in the management of acute TTP","volume":"137","author":"Dutt","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2021.08.347_bib0400","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1182\/bloodadvances.2020001973","article-title":"Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura","volume":"4","author":"V\u00f6lker","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.tracli.2021.08.347_bib0405","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1182\/blood.2020006052","article-title":"Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura","volume":"137","author":"Goshua","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2021.08.347_bib0410","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/rth2.12160","article-title":"Thrombotic thrombocytopenic purpura: toward targeted therapy and precision medicine","volume":"3","author":"Coppo","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.tracli.2021.08.347_bib0415","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/jth.15194","article-title":"Should all patients with immune-mediated thrombotic thrombocytopenic purpura receive caplacizumab?","volume":"19","author":"Picod","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.tracli.2021.08.347_bib0420","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMc1905426","article-title":"Caplacizumab therapy without plasma exchange for acquired thrombotic thrombocytopenic purpura","volume":"381","author":"Chander","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tracli.2021.08.347_bib0425","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1111\/jth.15045","article-title":"Treatment of acquired thrombotic thrombocytopenic purpura without plasma exchange in selected patients under caplacizumab","volume":"18","author":"V\u00f6lker","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.tracli.2021.08.347_bib0430","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1111\/trf.15823","article-title":"Caplacizumab for treatment of thrombotic thrombocytopenic purpura in a patient with anaphylaxis to fresh-frozen plasma","volume":"60","author":"Irani","year":"2020","journal-title":"Transfusion (Paris)"},{"key":"10.1016\/j.tracli.2021.08.347_bib0435","doi-asserted-by":"crossref","first-page":"536","DOI":"10.3390\/jcm10030536","article-title":"Thrombotic thrombocytopenic purpura: pathophysiology, diagnosis, and management","volume":"10","author":"Sukumar","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.tracli.2021.08.347_bib0440","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/blood.2020009150","article-title":"Redefining outcomes in immune TTP: an international working group consensus report","volume":"137","author":"Cuker","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2021.08.347_bib0445","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1182\/blood-2018-04-840090","article-title":"Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura","volume":"132","author":"Jestin","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2021.08.347_bib0450","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/bloodadvances.2017008268","article-title":"Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens","volume":"1","author":"Westwood","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.tracli.2021.08.347_bib0455","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1002\/ajh.26022","article-title":"Efficacy of subcutaneous preemptive rituximab in immune-mediated thrombotic thrombocytopenic purpura: experience from the first 12\u00a0cases","volume":"96","author":"Delrue","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.tracli.2021.08.347_bib0460","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1111\/bjh.17170","article-title":"Intensive rituximab regimen in immune-mediated thrombotic thrombocytopenic purpura can circumvent unresponsiveness to standard rituximab treatment","volume":"192","author":"Barba","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.tracli.2021.08.347_bib0465","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMc1714146","article-title":"Ofatumumab for TTP in a patient with anaphylaxis associated with rituximab","volume":"378","author":"Crowley","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tracli.2021.08.347_bib0470","doi-asserted-by":"crossref","first-page":"e259","DOI":"10.1002\/ajh.25583","article-title":"Obinutuzumab in two patients suffering from immune-mediated thrombotic thrombocytopenic purpura intolerant to rituximab","volume":"94","author":"Robertz","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.tracli.2021.08.347_bib0475","doi-asserted-by":"crossref","first-page":"17020","DOI":"10.1038\/nrdp.2017.20","article-title":"Thrombotic thrombocytopenic purpura","volume":"3","author":"Kremer Hovinga","year":"2017","journal-title":"Nat Rev Dis Primer"},{"key":"10.1016\/j.tracli.2021.08.347_bib0480","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/rth2.12066","article-title":"Novel therapies in thrombotic thrombocytopenic purpura","volume":"2","author":"Masias","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.tracli.2021.08.347_bib0485","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/rth2.12160","article-title":"Thrombotic thrombocytopenic purpura: toward targeted therapy and precision medicine","volume":"3","author":"Coppo","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.tracli.2021.08.347_bib0490","doi-asserted-by":"crossref","first-page":"160","DOI":"10.18632\/oncoscience.380","article-title":"Recombinant ADAMTS 13\u00a0in thrombotic thrombocytopenic purpura","volume":"4","author":"Scully","year":"2017","journal-title":"Oncoscience"},{"key":"10.1016\/j.tracli.2021.08.347_bib0495","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1111\/jth.13137","article-title":"Neutralization of inhibitory antibodies and restoration of therapeutic ADAMTS-13\u00a0activity levels in inhibitor-treated rats by the use of defined doses of recombinant ADAMTS-13","volume":"13","author":"Plaimauer","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.tracli.2021.08.347_bib0500","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/j.1538-7836.2011.04224.x","article-title":"Recombinant ADAMTS13\u00a0normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies","volume":"9","author":"Plaimauer","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.tracli.2021.08.347_bib0505","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1161\/ATVBAHA.115.306014","article-title":"Potential for recombinant ADAMTS13\u00a0as an effective therapy for acquired thrombotic thrombocytopenic purpura","volume":"35","author":"Tersteeg","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.tracli.2021.08.347_bib0510","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1056\/NEJMc1213206","article-title":"ADAMTS13\u00a0antibody depletion by bortezomib in thrombotic thrombocytopenic purpura","volume":"368","author":"Shortt","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tracli.2021.08.347_bib0515","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1172\/JCI41062","article-title":"N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice","volume":"121","author":"Chen","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.tracli.2021.08.347_bib0260","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1182\/blood-2016-09-738856","article-title":"N-acetylcysteine in preclinical mouse and baboon models of thrombotic thrombocytopenic purpura","volume":"129","author":"Tersteeg","year":"2017","journal-title":"Blood"}],"container-title":["Transfusion Clinique et Biologique"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1246782021004614?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1246782021004614?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:40:21Z","timestamp":1761129621000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1246782021004614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S1246782021004614"],"URL":"https:\/\/doi.org\/10.1016\/j.tracli.2021.08.347","relation":{},"ISSN":["1246-7820"],"issn-type":[{"type":"print","value":"1246-7820"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Traitement du purpura thrombotique thrombocytop\u00e9nique auto-immun\u00a0: un tournant d\u00e9cisif","name":"articletitle","label":"Article Title"},{"value":"Transfusion Clinique et Biologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tracli.2021.08.347","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Soci\u00e9t\u00e9 fran\u00e7aise de transfusion sanguine (SFTS). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}